We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
+6.72%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$277M
AUM Growth
-$15.6M
Cap. Flow
-$30.6M
Cap. Flow %
-11.02%
Top 10 Hldgs %
90.44%
Holding
15
New
2
Increased
5
Reduced
7
Closed
–

Top Buys

Rank Stock Value
1
SLN
Silence Therapeutics
SLN
+$13.3M
2
KYMR icon
Kymera Therapeutics
KYMR
+$8.7M
3
GMAB icon
Genmab
GMAB
+$1.05M
4
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$988K
5
ARWR icon
Arrowhead Research
ARWR
+$807K

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$12.3M
2
FDMT icon
4D Molecular Therapeutics
FDMT
+$7.77M
3
RGNX icon
Regenxbio
RGNX
+$5.93M
4
ARVN icon
Arvinas
ARVN
+$4.85M
5
QURE icon
uniQure
QURE
+$2.73M

Sector Composition

Rank Sector Weight
1 Healthcare 85.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
1
Arrowhead Research
ARWR
$12.4B
$40.3M 14.52%
1,218,515
+20,000
+2% +$807K
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$39.7M 14.3%
500,000
-250,000
-33% -$21.1M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$34.5M 12.45%
524,268
-192,271
-27% -$12.3M
MRUS
4
DELISTED
Merus
MRUS
$30.2M 10.88%
1,507,109
+30,000
+2% +$716K
ARVN icon
5
Arvinas
ARVN
$572M
$29.9M 10.77%
671,745
-100,000
-13% -$4.85M
RGNX icon
6
Regenxbio
RGNX
$708M
$25.6M 9.22%
967,684
-200,000
-17% -$5.93M
QURE icon
7
uniQure
QURE
$3.22B
$15.8M 5.69%
841,471
-130,019
-13% -$2.73M
AMYT
8
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$13.8M 4.99%
1,998,993
+132,341
+7% +$988K
SLN
9
Silence Therapeutics
SLN
$564M
$12.7M 4.57%
+1,263,125
New +$13.3M
ARGX icon
10
argenx
ARGX
$54.1B
$8.47M 3.05%
24,000
– –
GMAB icon
11
Genmab
GMAB
$19.5B
$7.87M 2.84%
244,848
+30,000
+14% +$1.05M
KYMR icon
12
Kymera Therapeutics
KYMR
$8.94B
$7.19M 2.59%
+330,246
New +$8.7M
SPRO icon
13
Spero Therapeutics
SPRO
$73M
$6.81M 2.45%
3,403,210
-1,918,021
-36% -$1.91M
PVLA
14
Palvella Therapeutics
PVLA
$2.27B
$4.64M 1.67%
50,454
+3,750
+8% +$483K
FDMT icon
15
4D Molecular Therapeutics
FDMT
$562M
$29K 0.01%
3,573
-858,034
-100% -$7.77M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Aquilo Capital Management held 15 positions worth $277M, down 5.3% from $293M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Aquilo Capital Management withdrew a net $30.6M in Q3 2022, reducing 7 holdings. Its largest reduction was Blueprint Medicines, cutting an estimated $12.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 81% a quarter earlier.

Against the trend, Aquilo Capital Management opened a new position in Silence Therapeutics worth $12.7M.

  • Aquilo Capital Management's largest Q3 2022 buy was Silence Therapeutics: 1,263,125 shares worth $12.7M.
  • Aquilo Capital Management added most to Genmab in Q3 2022, an estimated $1.05M increase.
  • Aquilo Capital Management's biggest Q3 2022 reduction was Blueprint Medicines, cutting an estimated $12.3M.
  • Aquilo Capital Management's ten largest holdings make up 90% of its $277M portfolio in Q3 2022.
  • Aquilo Capital Management opened 2 new positions and closed 0 in Q3 2022.
  • Aquilo Capital Management's portfolio value fell 5.3% quarter-over-quarter to $277M.

Based on Aquilo Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.